Overview

• U.S. biopharmaceutical firm's Q1 net loss per share was $0.32, clinical development on hold

• Company announced merger agreement with Eos SENOLYTIX, expected to close in Q3 2026

• General and administrative expenses fell yr/yr due to lower SEC filing costs

Outlook

• Pulmatrix expects proposed merger with Eos SENOLYTIX to close in Q3 2026

• Company says all clinical development is on hold while it seeks to license or monetize assets

• Pulmatrix anticipates cash position is sufficient to fund operations through expected merger closing

Result Drivers

• CLINICAL DEVELOPMENT ON HOLD - All clinical development paused as co seeks to license or monetize clinical assets

• LOWER ADMINISTRATIVE COSTS - General and administrative expenses fell yr/yr due to higher costs in prior year related to SEC filing preparation

• CAPITAL RAISE - Co secured $1 mln in gross proceeds from private placement of preferred stock

Company press release: ID:nPn15rp9pa

Key Details

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.